Agios Pharmaceuticals (AGIO) vs Braveheart Bio (BRVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Braveheart Bio is the larger company by market cap ($1.67 billion vs $1.65 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | BRVE |
|---|---|---|
| Share price | $27.60 | $20.39 |
| Market cap | $1.65B | $1.67B |
| 1-day change | -4.03% | +5.81% |
| YTD return | +1.40% | — |
| 1-year return | +9.35% | — |
| 5-year return | -24.28% | — |
| EPS (TTM) | $-6.31 | $-6.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $54.03M | — |
| Revenue growth (YoY) | +48.03% | — |
| Net income (latest FY) | $-412.78M | — |
| Gross margin | 88.26% | — |
| Operating margin | -873.87% | — |
| Net margin | -764.01% | — |
| 52-week high | $44.09 | $32.00 |
| 52-week low | $24.16 | $16.70 |
| Distance from 52-week high | -37.40% | -36.28% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +67.07% | +123.15% |
| Average volume | 1.06M | 491.27K |
| Shares outstanding | 59.81M | 82.07M |
| Employees | 539 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
AGIO vs BRVE FAQ
Which is bigger, Agios Pharmaceuticals or Braveheart Bio?
Braveheart Bio (BRVE) is larger, with a market capitalization of $1.67B compared with $1.65B for Agios Pharmaceuticals (AGIO).
Are Agios Pharmaceuticals and Braveheart Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.